# Hydralazine Valproate for Cervical Cancer

> **NCT00532818** · PHASE3 · UNKNOWN · sponsor: **National Institute of Cancerología** · enrollment: 143 (estimated)

## Conditions studied

- Metastatic Cervical Cancer

## Interventions

- **DRUG:** Hydralazine and magnesium valproate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00532818
- **Lead sponsor:** National Institute of Cancerología
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-07
- **Primary completion:** 2010-09
- **Final completion:** 2010-12
- **Target enrollment:** 143 (ESTIMATED)
- **Last updated:** 2009-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532818, "Hydralazine Valproate for Cervical Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00532818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*